BiotechTube

ALIMTA + folic acid + multi-vitamins

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastases

Conditions

Metastases, Cancer

Trial Timeline

— → —

NCT ID
NCT00034463

About ALIMTA + folic acid + multi-vitamins

ALIMTA + folic acid + multi-vitamins is a phase 1 stage product being developed by Eli Lilly for Metastases. The current trial status is completed. This product is registered under clinical trial identifier NCT00034463. Target conditions include Metastases, Cancer.

What happened to similar drugs?

0 of 12 similar drugs in Metastases were approved

Approved (0) Terminated (0) Active (12)
🔄Denosumab + Zoledronic AcidDaiichi SankyoPhase 3
🔄Leuprorelin AcetateAstellas PharmaPhase 3
🔄Zoledronic acidNovartisPhase 3
🔄capecitabine + lapatinib + trastuzumabNovartisPhase 3
🔄Denosumab + Zoledronic AcidAmgenPhase 3
🔄zoledronic acid + denosumabAmgenPhase 3
🔄amg 162AmgenPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00034463Phase 1Completed

Competing Products

20 competing products in Metastases

See all competitors
ProductCompanyStageHype Score
LY2780301Eli LillyPhase 1
29
Abemaciclib + Endocrine therapyEli LillyPhase 1/2
39
Patritumab deruxtecanDaiichi SankyoPhase 2
27
Trastuzumab deruxtecanDaiichi SankyoPhase 2
35
Denosumab + Zoledronic AcidDaiichi SankyoPhase 3
40
Leuprorelin AcetateAstellas PharmaPhase 3
44
Pembrolizumab + LenvatinibEisaiPhase 2
42
MerestinibEli LillyPhase 1
21
LY2584702 + Erlotinib + EverolimusEli LillyPhase 1
21
Veliparib + PlaceboAbbViePhase 2
35
temozolomideMerckPhase 2
27
VorinostatMerckPhase 1
29
PembrolizumabMerckPhase 2
39
EMD 525797MerckPhase 1
29
TemozolomideMerckPhase 2
35
cabazitaxel + lapatinibNovartisPhase 2
27
BKM120 + capecitabine + TrastuzumabNovartisPhase 2
35
Zoledronic acidNovartisPhase 3
40
zoledronic acidNovartisPhase 1
29
capecitabine + lapatinib + trastuzumabNovartisPhase 3
40